Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ondrej, Venclicek"'
Autor:
Martin Svaton, Marie Drosslerova, Ondrej Fischer, Miloslav Marel, Michal Hrnciarik, Ondrej Venclicek, Petr Zuna, Michal Svoboda, Jiri Blazek, Monika Bratova, Andrea Mullerova, Bohuslava Vankova, Daniel Krejci
Publikováno v:
Translational Cancer Research. 11:3017-3023
Programmed death-ligand 1 (PD-L1) expression is a standard predictor in the selection of immunotherapy for locally advanced/advanced non-small cell lung cancer (NSCLC). However, comedication with corticosteroids or non-steroidal anti-inflammatory dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3c76b30c1029f4fe5ea5a3bea55b5cb
https://doi.org/10.21037/tcr-22-260
https://doi.org/10.21037/tcr-22-260
Autor:
Miloslav, Marel, Zdenka, Chladkova, Luis Fernando, Casas Mendez, Ondrej, Venclicek, Jana, Skrickova, Ondej, Fischer, Andrea, Mullerova, Libor, Havel, Zuzana, Gyorfy, Michal, Hrnciarik, Michal, Jirousek, Jana, Krejci, Daniel, Krejci, Marcela, Buresova, Jana, Alahakoon, Michal, Svoboda, Martin, Svaton
Publikováno v:
Cancer Diagn Progn
Background/Aim: This study aimed at contributing to a better diagnosis of lung cancer by analyzing the patient’s symptoms and their linkage to other characteristics. Patients and Methods: We analyzed the data of 3,322 patients from LUCAS (LUngCAnce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcbbcfd1d35bc0b8c7f86a95fb3c89a8
https://doi.org/10.21873/cdp.10091
https://doi.org/10.21873/cdp.10091
Autor:
Denisa Rozsivalova, Jana Alahakoon, Juraj Kultan, Andrea Mullerova, Kristián Brat, Daniel Krejci, Ondrej Venclicek, Libor Havel, Martin Svaton, Martina Vasakova, Petra Smickova, Ondrej Fischer, Kristyna Hrda, Jana Skrickova, Zsuzsanna Gyorfy, Miloslav Marel, Gabriela Krakorova, P. Opálka, Michal Hrnčiarik, Jaroslav Duba, Jiri Silar, Michal Svoboda, Michal Jirousek, Petr Zuna, J. Krejčí, Lydia Zarnayova
Publikováno v:
Anticancer Research. 41:5549-5556
Background/aim LUCAS is a clinical lung cancer registry (ClinicalTrials.gov identifier is NCT04228237), prospectively collecting data from newly diagnosed lung cancer patients in seven pneumooncology centers in the Czech Republic, since June 1, 2018.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f45687a837ce2677c1d91847fb2d1fe
https://doi.org/10.21873/anticanres.15368
https://doi.org/10.21873/anticanres.15368
Autor:
MARTIN SVATON, MARIE DROSSLEROVA, ONDREJ FISCHER, MILOSLAV MAREL, MICHAL HRNCIARIK, ONDREJ VENCLICEK, PETR ZUNA, MICHAL SVOBODA, JIRI BLAZEK, MONIKA BRATOVA, ANDREA MULLEROVA, BOHUSLAVA VANKOVA, DANIEL KREJCI
Publikováno v:
Anticancer research. 42(3)
Due to some interconnectedness at the molecular level, this study assessed the possible influence of laboratory parameters associated with systemic inflammatory environment on programmed death-ligand 1 (PD-L1) expression in non-small cell lung carcin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c4184b9ff80077212171f01b6af07bd
https://pubmed.ncbi.nlm.nih.gov/35220253
https://pubmed.ncbi.nlm.nih.gov/35220253